Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novartis, Lilly lead a $44M round for rare disease biotech Aeglea
Novartis, Lilly lead a $44M round for rare disease biotech Aeglea
Novartis, Lilly lead a $44M round for rare disease biotech Aeglea
Submitted by
admin
on March 24, 2015 - 10:22am
Source:
Fierce Biotech
News Tags:
Novartis
Eli Lilly
Aeglea
Headline:
Novartis, Lilly lead a $44M round for rare disease biotech Aeglea
Do Not Allow Advertisers to Use My Personal information
